JP7650001B2 - ｍＲＮＡ製剤 - Google Patents

ｍＲＮＡ製剤 Download PDF

Info

Publication number
JP7650001B2
JP7650001B2 JP2021563262A JP2021563262A JP7650001B2 JP 7650001 B2 JP7650001 B2 JP 7650001B2 JP 2021563262 A JP2021563262 A JP 2021563262A JP 2021563262 A JP2021563262 A JP 2021563262A JP 7650001 B2 JP7650001 B2 JP 7650001B2
Authority
JP
Japan
Prior art keywords
mrna
pseudouridine
thio
methyl
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021563262A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532038A5 (enExample
JP2022532038A (ja
Inventor
コケル，ステファン デ
ビーバース，サンネ
トム，ピーター
Original Assignee
イーザアールエヌーエー イムノセラピーズ エンヴェー
ヴリジェ ユニヴェルシテ ブリュッセル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーザアールエヌーエー イムノセラピーズ エンヴェー, ヴリジェ ユニヴェルシテ ブリュッセル filed Critical イーザアールエヌーエー イムノセラピーズ エンヴェー
Publication of JP2022532038A publication Critical patent/JP2022532038A/ja
Publication of JP2022532038A5 publication Critical patent/JP2022532038A5/ja
Application granted granted Critical
Publication of JP7650001B2 publication Critical patent/JP7650001B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021563262A 2019-04-26 2020-04-24 ｍＲＮＡ製剤 Active JP7650001B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19171323 2019-04-26
EP19171323.9 2019-04-26
PCT/EP2020/061477 WO2020216911A1 (en) 2019-04-26 2020-04-24 Mrna formulation

Publications (3)

Publication Number Publication Date
JP2022532038A JP2022532038A (ja) 2022-07-13
JP2022532038A5 JP2022532038A5 (enExample) 2023-04-24
JP7650001B2 true JP7650001B2 (ja) 2025-03-24

Family

ID=66290283

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563262A Active JP7650001B2 (ja) 2019-04-26 2020-04-24 ｍＲＮＡ製剤

Country Status (12)

Country Link
US (1) US20220362360A1 (enExample)
EP (1) EP3958893A1 (enExample)
JP (1) JP7650001B2 (enExample)
KR (1) KR20220023340A (enExample)
CN (1) CN114096272B (enExample)
AU (1) AU2020263948B2 (enExample)
BR (1) BR112021021262A2 (enExample)
CA (1) CA3138011A1 (enExample)
IL (1) IL287560B2 (enExample)
MX (1) MX2021013018A (enExample)
SG (1) SG11202111720TA (enExample)
WO (1) WO2020216911A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7496623B2 (ja) * 2019-01-04 2024-06-07 イーザアールエヌーエー イムノセラピーズ エンヴェー ｍＲＮＡワクチン
US20220143161A1 (en) * 2019-03-13 2022-05-12 Etherna Immunotherapies Nv Mrna vaccine
CN119701015A (zh) * 2023-09-26 2025-03-28 深圳瑞吉生物科技有限公司 一种细胞因子mRNA组合药物及其应用
CN121873266A (zh) * 2026-03-18 2026-04-17 北京悦康科创医药科技股份有限公司 一种增强肿瘤疫苗免疫原性的嵌合多肽及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180133311A1 (en) 2007-09-14 2018-05-17 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
JP2018529738A (ja) 2015-10-05 2018-10-11 モデルナティーエックス， インコーポレイテッド メッセンジャーリボ核酸薬物の治療投与のための方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2201100E (pt) * 2007-09-14 2016-06-03 Univ Brussel Vrije Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação
US20130108663A1 (en) * 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
EP3173474A1 (en) * 2007-09-14 2017-05-31 Vrije Universiteit Brussel Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
WO2015071295A1 (en) 2013-11-12 2015-05-21 Vrije Universiteit Brussel Rna transcription vector and uses thereof
DK4276189T3 (da) * 2015-09-21 2026-05-26 Trilink Biotechnologies Llc Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180133311A1 (en) 2007-09-14 2018-05-17 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
JP2018529738A (ja) 2015-10-05 2018-10-11 モデルナティーエックス， インコーポレイテッド メッセンジャーリボ核酸薬物の治療投与のための方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
mBio，2016年，Vol.7, Issue 5，e00833-16 (pp.1-11)，doi:10.1128/mBio.00833-16
Molecular Therapy，2008年，vol.16 no.11，pp.1833-1840，doi:10.1038/mt.2008.200
Molecular Therapy: Nucleic Acids，2018年，Vol.12，pp.530-542，https://doi.org/10.1016/j.omtn.2018.06.010
Scientific Reports，2016年，Vol.6, 22509，pp.1-15，DOI: 10.1038/srep22509

Also Published As

Publication number Publication date
BR112021021262A2 (pt) 2021-12-21
SG11202111720TA (en) 2021-11-29
AU2020263948B2 (en) 2026-06-25
CN114096272B (zh) 2024-08-06
EP3958893A1 (en) 2022-03-02
CN114096272A (zh) 2022-02-25
WO2020216911A1 (en) 2020-10-29
IL287560B2 (en) 2026-02-01
US20220362360A1 (en) 2022-11-17
AU2020263948A1 (en) 2021-12-23
MX2021013018A (es) 2022-03-11
CA3138011A1 (en) 2020-10-29
IL287560B1 (en) 2025-10-01
JP2022532038A (ja) 2022-07-13
KR20220023340A (ko) 2022-03-02
IL287560A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
CN114096272B (zh) mRNA制剂
US20240325522A1 (en) Rna adsorbed onto lipid nano-emulsion particles and its formulations
JP2019515900A (ja) がんを処置するためのＴｏｌｌ様レセプター９アゴニストおよび腫瘍抗原を含む粒子の腫瘍内送達
KR20180094859A (ko) 수두 대상포진 바이러스 (vzv)를 위한 핵산 백신
CN115820696A (zh) 治疗性多价HPV mRNA疫苗及其制备方法
CN119563028A (zh) 具有分泌抗原和免疫调节物的合成自扩增mRNA分子
CN119654141A (zh) 脂质纳米颗粒的组合物
AU2022422532A1 (en) Immunostimulatory mrna compositions and uses thereof
WO2021095838A1 (ja) ＨＰＶ ｍＲＮＡを封入した核酸脂質粒子ワクチン
JP2026500600A (ja) Ｈｐｖ感染関連疾患を予防又は治療するためのポリヌクレオチド分子
EP4326308A2 (en) Nanoparticles for antigen-specific cell programming and uses thereof
JP2026512425A (ja) 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
Cui et al. From design to clinical use: mRNA vaccines for infectious diseases and cancer
WO2025140126A1 (en) Therapeutic ly6k mrna vaccine for cancer
Cheng et al. Topical CpG adjuvantation of a protein-based vaccine induces protective immunity to Listeria monocytogenes
JP2023502925A (ja) 生体内遺伝子治療のためのポリマー封入ウイルスベクター
HK40068420B (en) Mrna formulation
HK40068420A (en) Mrna formulation
CN121620389A (zh) 一种针对MICA/B靶点的mRNA肿瘤疫苗
CN118340876A (zh) 一种水痘-带状疱疹病毒的自复制mRNA疫苗药物组合物及其应用
WO2025146130A1 (en) Therapeutic BIRC5 mRNA Vaccine for Cancer
WO2024020453A2 (en) Immune system modulators and uses thereof
JP2025508829A (ja) 負に帯電した粒子による固形腫瘍の治療
KR20260006603A (ko) 융합전 안정화된 cmv gb 단백질 나노구조체
HK40108427A (en) Polynucleotide molecule for preventing or treating hpv infection-related diseases

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20211129

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220628

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240619

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241203

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250228

R150 Certificate of patent or registration of utility model

Ref document number: 7650001

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150